The expression of PLA2G7 may represent an integral biomarker in diffuse large B-cell lymphoma (DLBCL), according to a study published in BMC Cancer.
In this study, differently expressed DLBCL genes were discerned using two GEO datasets in an effort to detect novel diagnostic or prognostic biomarkers. The expression of PLA2G7 in DLBCL patient clinical samples was assessed, as was the functional role of this gene in DLBCL.
According to the results, DLBCL-related DEGs were found to be most closely associated with immune responses, cell proliferation, and angiogenesis. The analysis demonstrated that PLA2G7 exhibited prognostic value in DLBCL patients, and the upregulation of this gene in DLBCL patient samples was validated. Also, PLA2G7 was observed to be closely linked to tumor microenvironmental composition. In vitro experiments revealed that knocking down PLA2G7 expression was sufficient to impair the DLBCL cell migration and proliferation while promoting their apoptotic death.
“PLA2G7 may represent an important diagnostic, prognostic, or therapeutic biomarker in patients with DLBCL,” the researchers wrote.